ZBiotech Lectin Array: Binding specificities of the lectins on the array

ID	Lectin	Binding Specificity
NL1	AAL	Fucose-containing glycans; no binding to fucose on Blood Group A and B antigens except minor binding to type 2 antigens
NL2	AIA	O-glycans containing the following motifs: T antigen (Core 1); Tn antigen; O-GalNAc Core 3; no binding to STn, Core 2, Core 4 and Core 6 O-GalNAc glycans, Blood Group ABH Antigens Type 3
NL3	BC2L-C	Fucose; no or weak binding to Blood Group A and B type 2 antigens
NL4	BPL	Terminal β-Gal/β-GalNAc: PolyLacNAc > Mono/Di LacNAc. Sialic acid attached to Gal shields the binding. Fucose attached to GlcNAc allows the binding; no binding to Blood Group Antigens.
NL5	Calsepa	Bind to N-glycans; no difference between bisecting N-glycans, complex N-glycans and core-fucose N-glycans.
NL6	ConA	High-mannose, complex, hybrid, bisecting N-glycans; no binding to tri- and tetra-antennary N-glycans.
NL7	DBA	Glycans with Sd^a antigen motif (e.g., GM2); Blood Group A antigen
NL8	DSA	Type 2 LacNAc; $(GlcNAc\beta1\text{-}4)_2$ and some extended epitopes; bind to Blood Group antigens A, B, H, Type 2.
NL9	ECL	Terminal β1,4-Gal; no binding to Lewis X; bind to Blood Group Antigen H Type 2
NL10	GNA	Exposed α1,3-Man on N-glycans
NL11	GSI-B4	Terminal α1,3-Gal (or weaker α1,4-Gal); bind to Blood Group B Antigens
NL12	GSII	Terminal GlcNAc
NL13	HAA	Terminal α-GalNAc: Blood Group A > GalNAca1-3GalNAcb > All other α-GalNAc; Similar to HPA.
NL14	HHL	High Mannose N-glycans; Weak binding to Complex (non-bisecting GlcNAc) N-Glycans and other mannose polysaccharides; no binding to bisecting N-glycans.
NL15	HPA	Terminal GalNAc; weak binding to T antigen; no binding to Sda antigen, Blood Group A Antigen. Similar to HAA.
NL16	LCA	Core-fucose N-glycans; High-mannose N-glycans
NL17	LEL	LacNAc, including Blood Group ABH antigens; weak binding to High-mannose N-glycans; α2,3-sialylated type 2 poly-LacNAc
NL18	LTA	Terminal Fucα1-3GlcNAc; Lewis X; Lewis Y; Blood Group H disaccharide, Type 2 and 6.
NL19	MAL-I	Terminal Neu5Ac(or Neu5Gc)α2-3Galβ1-4GlcNAc(or Glc), or 3'-sulfates; weak asialo partial-epitope binding; no binding to SLeX or Sd^a antigen
NL20	MAL-II	Terminal Neu5Ac(or Neu5Gc)α2-3Galβ1-4GlcNAc(or Glc), or 3'-sulfates; weak asialo partial-epitope binding; no binding to SLeX or Sd^a antigen
NL21	Morniga G	High-mannose N-glycan > Poly-LacNAc N-glycan > Tri-antennary N-glycans.
NL22	NPA	High-mannose N-glycans > Hybrid N-glycans > Core-fucose N-glycans
NL23	PHA-E	Complex N-Glycans; no high-mannose binding
NL24	PHA-L	Bisecting N-glycans
NL25	PNA	Galβ1-3GalNAc (T antigen)
NL26	PSA	Core N-Glycan Fucose (Fuca1-6GlcNAc). No binding to non-fucosylated N-Glycans.
NL27	PTA	Bind to Blood Group H antigens except Type 1.
NL28	RCA-I	Terminal β1,4-Gal (β1,3 and β1,6 also accepted); no binding with terminal α2,3 sialic acid, or to T antigen or Lewis X; still binds to β1,4-Gal capped with terminal α2,6 sialic acid or 6'-sulfate.
NL29	RPA	Complex N-Glycans: Tetra-antennary > Tri-antennary; weak binding to Poly-LacNAc extended bi-antennary; no Other bi-antennary N-Glycan binding.
NL30	RSL	Fucose-containing glycans; includes all blood group fucose, core N-Glycan fucose ,and Lewis A/X Fucose
NL31	SBA	Terminal α-GalNAc or β-GalNAc; Tn antigen; MUC-1 glycopeptides; similar to VVL
NL32	SNA	Terminal Neu5Ac(or Neu5Gc)α2-6Galβ1-4; no asialo partial-epitope binding.
NL33	STL	Galβ1-4GlcNAc (type 2 poly-LacNAc) with weak partial-epitope binding; weak binding to High-mannose N-Glycans (GlcNAcB1-4GlcNAc epitope); bind to Blood Group ABH antigens type 2.
NL34	UEA-I	Fucα1-2Galβ1-4GlcNAc (Blood Group H Type 2, 5, 6, disaccharide); Lewis Y; α1,4-Fuc
NL35	VVL	Tn antigen; weak binding to blood group antigen A
NL36	WFA	Terminal GalNAc; terminal β-Gal on LacNAc; no binding to Lewis X. bind to Sd^a antigen; no T antigen binding.
NL37	WGA	GlcNAc; terminal and exposed α2,3-Neu5Ac; terminal and exposed α-GalNAc; no binding to Lewis X; no binding with terminal α2,6 sialic acid.